Baseline demographic and clinical characteristics of both groups*
| COVID-19-positive status (N=222) | COVID-19-negative status (N=216) | |
| Characteristics | ||
| Age (years) | 68.0 (56–78) | 69.0 (53.8–81.3) |
| 20–39, n (%) | 16 (7.2) | 24 (11.1) |
| 40–49, n (%) | 18 (8.1) | 18 (8.3) |
| 50–59, n (%) | 38 (17.7) | 21 (9.7) |
| 60–69, n (%) | 47 (21.2) | 42 (19.4) |
| 70–79, n (%) | 51 (23.0) | 43 (19.9) |
| 80–89, n (%) | 40 (18.0) | 50 (23.1) |
| ≥90, n (%) | 12 (5.4) | 14 (6.5) |
| Female gender, n (%) | 85 (38.3) | 102 (47.2) |
| BMI (kg/m2)† | 27.6 (24.0–31.6) | 26.1 (22.4–31.2) |
| Comorbidities, n (%) | ||
| Hypertension | 113 (50.9) | 108 (50.0) |
| Obesity (BMI≥30) | 48 (21.6) | 51 (23.6) |
| Morbid obesity (BMI≥35) | 20 (9.0) | 21 (9.7) |
| Diabetes | 45 (20.3) | 50 (23.1) |
| Number of home medications | 4.0 (1.0–7.3) | 6.0(3.0–10.0) |
| Age intervals (years) | ||
| 20–39 | 0.5 (0.0–1.0) | 1.5 (0.0–6.0) |
| 40–49 | 1.0 (0.0–2.0) | 3.0 (2.0–7.0) |
| 50–59 | 3.0 (0.3–6.0) | 4.0 (1.0–6.0) |
| 60–69 | 3.0 (1.0–7.8) | 8.0 (4.0–11.0) |
| 70–79 | 5.0 (2.0–8.0) | 10.0 (6.0–12.0) |
| 80–89 | 6.0 (4.0–8.5) | 7.0 (5.0–9.0) |
| ≥90 | 8.0 (6.0–8.3) | 6.0 (5.0–7.8) |
*Data presented as medians (quartile 1–quartile 3).
†Data available for 306 patients.
BMI, Body Mass Index.